Discovering drugs to treat coronavirus disease 2019 (COVID-19)

Dong, Liying; Hu, Shasha; Gao, Jianjun

doi:10.5582/ddt.2020.01012

Cited by 1,244 publications

(1,225 citation statements)

References 11 publications

Supporting

Mentioning

1,165

Contrasting

Unclassified

Order By: Relevance

“…for treat ment of COVID-19 reco mmends chloroquine phosphate is orally ad min istered at a dose of 500 mg (300 mg for chloroquine) for adults, 2 times/ day (no more than 10 days) [39]. The results of this clinical trial confirmed the short -term efficacy of HCQ in the treat ment of COVID-19, wh ich can effectively improve lung imag ing findings, promote a virus -negative conversion, and shorten the disease course.…”

Section: Jak Inhibitorsmentioning

confidence: 99%

The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China

Zhang¹,

Zhao²,

Zhang³

et al. 2020

Clinical Immunology

1,225

1,341

View full text Add to dashboard Cite

The pandemic outbreak of coronavirus disease 2019 is rap idly spreading all over the world. Reports from China showed that about 20% of patients developed severe disease, resulting in a fatality of 4%. In the past two months, we clinical immunologists participated in mu lti-rounds of MDT (mult idiscipline team) discussion on the anti-inflammat ion management of critical ill COVID-19 patients, with our colleagues dispatched from Ch inese leading PUM C Hospital to Wuhan to admit and treat the most severe patients . Here, fro m the perspective of clinical immunologists, we will discuss the clin ical and immunological characteristics of severe patients, and summarize the current evidence and share our experience in anti-inflammat ion treatment, including glucocorticoids, IL-6 antagonist, JAK inhibitors and choloroquine/hydrocholoroquine, of patients with severe COVID-19 that may have an impaired immune system.

show abstract

Section: Jak Inhibitorsmentioning

confidence: 99%

The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China

Zhang¹,

Zhao²,

Zhang³

et al. 2020

Clinical Immunology

1,225

1,341

View full text Add to dashboard Cite

show abstract

“…Subtype diversity could be another explanation of inconsistencies between studies. It was repeatedly shown that IFNβ is a more potent inhibitor of coronaviruses than IFNα (Scagnolari et al, 2004;Stockman et al, 2006): depending on the studies, IFNβ1b or IFNβ1a were the most potent IFN-I subtype in the inhibition of SARS-CoV (Hensley et al, 2004) and MERS-CoV (Chan et al, 2013;Dong et al, 2020;Hart et al, 2014). Consequently, IFNβ1 appears to be most relevant interferon to treat coronavirus infections.…”

Section: Main Textmentioning

confidence: 99%

Type 1 interferons as a potential treatment against COVID-19

et al. 2020

View full text Add to dashboard Cite

“…Ultimately, development of an effective anti-viral for SARS-CoV-2, if given to patients early in infection, could help to limit the viral load, prevent severe disease progression and limit person-person transmission. Benchmarking testing of ivermectin against other potential antivirals for SARS-CoV-2 with alternative mechanisms of action (Dong et al, 2020;Elfiky, 2020;Gordon et al, 2020;Li and De Clercq, 2020;Wang et al, 2020) would thus be important as soon as practicable. This Brief Report raises the possibility that ivermectin could be a useful antiviral to limit SARS-CoV-2, in similar fashion to those already reported (Dong et al, 2020;Elfiky, 2020;Gordon et al, 2020;Li and De Clercq, 2020;Wang et al, 2020); until one of these is proven to be beneficial in a clinical setting, all should be pursued as rapidly as possible.…”

Section: Introductionmentioning

confidence: 99%